- Significant sales and EBIT growth
- EBITDA at 27.1% and EBIT at 18.2% of sales
- Capital increase boosts equity ratio
- Potentially record-breaking second half expected
- Annual targets confirmed
- Another strong fiscal year anticipated
August 23rd, 2019
Are you ready to dive into the fascinating universe of peptides and oligonucleotides?
Sign up for our newsletter and receive the latest updates directly in your inbox.
"*" indicates required fields